IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice.

德克萨斯州欧文市——（商业新闻短讯）——麦克森公司（纽约证券交易所：MCK）今天宣布，它签署了一项最终协议，收购社区肿瘤振兴企业风险投资有限责任公司（Core Ventures）的控股权。Core Ventures是一家商业和行政服务组织，由佛罗里达癌症专家与研究所有限责任公司（FCS）成立，FCS是一家领先的医生拥有的社区肿瘤学实践机构。

FCS physicians will continue to retain a minority interest in Core Ventures..

FCS医生将继续在核心企业中保留少数股权。。

McKesson will purchase its controlling interest for approximately $2.49 billion in cash, which will represent approximately 70% ownership. Following completion of the transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within McKesson’s US Pharmaceutical segment.

McKesson将以约24.9亿美元现金收购其控股权益，约占70%的所有权。交易完成后，核心企业将成为肿瘤学平台的一部分，财务结果将在麦凯森的美国制药部门报告。

The transaction is subject to customary closing conditions, including necessary regulatory clearances. Following the close of the transaction, FCS, a practice with more than 250 physicians and 280 advanced practice providers, across nearly 100 locations in Florida, will remain independently owned and FCS will join McKesson’s The US Oncology Network (The Network), a leading oncology organization, dedicated to advancing local and affordable cancer care and better patient outcomes..

该交易受惯例成交条件的约束，包括必要的监管许可。交易结束后，佛罗里达州近100个地点拥有250多名医生和280名高级实践提供者的FCS将继续独立拥有，FCS将加入McKesson的美国肿瘤学网络（the Network），这是一家领先的肿瘤学组织，致力于推进当地和负担得起的癌症护理，改善患者预后。。

“This milestone marks an important step forward in our efforts to advance community-based oncology care,” said Brian Tyler, chief executive officer, McKesson. “By growing our Oncology platform, we will bring advanced treatments and improved care experiences to patients, while also reducing the overall cost of care.

麦克森首席执行官布莱恩·泰勒（BrianTyler）表示：“这一里程碑标志着我们在推进社区肿瘤护理方面迈出了重要的一步。”。“通过扩大我们的肿瘤学平台，我们将为患者带来先进的治疗和改进的护理体验，同时也降低了整体护理成本。

FCS and Core Ventures’ expertise and patient-first approach align with our commitment to accelerating clinical development, improving patient outcomes, and expanding access to quality cancer care in the community. We are also pleased to welcome Florida Cancer Specialists & Research Institute to The US Oncology Network, reinforcing our dedication to empowering community-based providers to independently thrive in today’s rapidly evolving healthcare landscape.”.

FCS和Core Ventures的专业知识和患者至上的方法与我们加速临床开发，改善患者预后以及扩大社区获得优质癌症护理的承诺相一致。我们也很高兴欢迎佛罗里达州癌症专家和研究所加入美国肿瘤学网络，加强我们致力于增强社区提供者在当今快速发展的医疗保健领域中独立发展的能力。”。

FCS has provided exceptional care to cancer patients for over 40 years. During that time, services have grown to include clinical trials, diagnostic imaging, medical oncology and chemotherapy infusion, integrative therapy, molecular and pathology lab services, radiation oncology, next-generation sequencing, medically integrated dispensing, and data services.

FCS为癌症患者提供了40多年的特殊护理。在此期间，服务已经发展到包括临床试验、诊断成像、医学肿瘤学和化疗输注、综合治疗、分子和病理学实验室服务、放射肿瘤学、下一代测序、医学综合配药和数据服务。

FCS currently conducts clinical trials through Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. By joining The Network, FCS will have access to McKesson’s differentiated Oncology platform, including best-in-class oncology care products and services..

FCS目前通过Sarah Cannon Research Institute（SCRI）进行临床试验，该研究所是进行社区临床试验的世界领先肿瘤学研究组织之一。通过加入该网络，FCS将可以访问McKesson的差异化肿瘤学平台，包括一流的肿瘤学护理产品和服务。。

“Above all else, our patients are the true beneficiaries of this transaction, as we seek to drive meaningful outcomes and deliver sustained value with every interaction. Through the power of our combined operational expertise, we can bolster community oncology's role in increasing access to high-quality, affordable care,” said Lucio N.

“最重要的是，我们的患者是这项交易的真正受益者，因为我们寻求推动有意义的结果，并通过每次互动提供持续的价值。通过我们综合运营专业知识的力量，我们可以加强社区肿瘤学在增加获得高质量，负担得起的护理方面的作用，”Lucio N说。

Gordan, MD, president and managing physician, FCS..

Gordan，医学博士，FCS总裁兼管理医师。。

“This is a historic moment for FCS and reflects the evolution of our practice and the forward-thinking of physician leadership, our board, and the entire organization at large,” said Nathan H. Walcker, chief executive officer of FCS. “The US Oncology Network and FCS share a mission and we both aim to strengthen patient-centered cancer care in the community to improve outcomes.

FCS首席执行官内森·沃尔克（NathanH.Walcker）表示：“这对FCS来说是一个历史性的时刻，反映了我们实践的演变以及医生领导力、董事会和整个组织的前瞻性思维。”。“美国肿瘤学网络和FCS有着共同的使命，我们都致力于加强社区以患者为中心的癌症护理，以改善结果。

We are thrilled to partner with McKesson and join The Network, which furthers the joint commitment to bringing the best medicine and innovation for patients into communities across Florida.”.

我们很高兴与McKesson合作并加入该网络，这进一步推动了将最佳药物和创新带给佛罗里达州社区的共同承诺。”。

Cautionary Statements

警示性声明

Except for historical information, statements in this press release regarding McKesson’s proposed acquisition and related arrangements constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements.

除历史信息外，本新闻稿中有关McKesson拟议收购和相关安排的声明构成《1933年证券法》第27A节和《1934年证券交易法》第21E节所指的“前瞻性声明”，涉及风险和不确定性，可能导致实际结果与这些声明中的结果存在重大差异。

It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements.

不可能识别所有此类风险和不确定性。读者不应过度依赖前瞻性陈述，因为前瞻性陈述仅在首次发表之日起生效。除法律要求外，公司不承担公开更新前瞻性声明的义务。

We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may be unable to obtain necessary regulatory approvals; we may not achieve expected outcomes from the transaction; we might be adversely impacted by delays or other difficulties, including related to the transactions described in this press release; we from time to time record significant charges from impairment to goodwill, intangibles and other assets or investments; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, economic events and other catastrophic events..

我们鼓励投资者阅读公司向证券交易委员会提交的最新10-K表中描述的重要风险因素。这些风险因素包括但不限于：我们可能无法获得必要的监管批准；；我们可能会受到延迟或其他困难的不利影响，包括与本新闻稿中描述的交易有关；我们不时记录商誉、无形资产和其他资产或投资减值的重大费用；我们可能会受到我们无法控制的事件的不利影响，例如广泛的公共卫生问题、自然灾害、政治事件、经济事件和其他灾难性事件。。

About McKesson

关于McKesson

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.

McKesson Corporation是一家多元化医疗服务的领导者，致力于为世界各地的患者改善健康状况。我们的团队与生物制药公司、护理提供者、药店、制造商、政府和其他人合作，提供见解、产品和服务，以帮助使优质护理更容易获得和负担得起。

Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories..

在McKesson.com上了解更多关于McKesson如何影响医疗保健的各个方面，并阅读我们的故事。。

About McKesson Oncology and Specialty Solutions

关于McKesson肿瘤学和专业解决方案

It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need.

对于癌症患者来说，这是一个前所未有的时代，因为生命科学公司正在争相创造新的尖端疗法。随着癌症护理越来越有针对性，提供者，生命科学公司和付款人在开发新疗法并使有需要的患者能够获得这些疗法方面面临着众多挑战和复杂性。

At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care..

在麦凯森，我们无与伦比的肿瘤学业务和合作伙伴组合提供研究、见解、技术和服务，帮助解决这些障碍，改善癌症和专科护理。。

McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute.

麦凯森通过与莎拉·坎农研究所（SarahCannonResearch Institute）的合资企业，帮助患者在离家较近的地方参与尖端临床试验，从而推动了这一发现。

The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.

美国肿瘤学网络和McKesson提供者解决方案通过支持数千名独立的社区提供者的实践，正在患者居住的社区推进专科护理和高质量的癌症护理。

Ontada®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care.

Ontada®是一家专注于肿瘤学的McKesson企业，它可以生成真实世界的数据（RWD）和真实世界的证据（RWE），并提供临床教育和提供者技术，以告知和改善癌症护理。

As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.

作为最大的肿瘤和特药分销商之一，我们正在确保将药品送到那些需要它们的人手中。

And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.

通过CoverMyMeds、McKesson的生物制剂和GPO服务，我们的工作继续帮助患者获得、负担和坚持他们的药物。